Literatur
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
Foerster F, Gairing SJ, Müller L, Galle PR (2022) NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 76:446–457. https://doi.org/10.1016/j.jhep.2021.09.007
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7:6. https://doi.org/10.1038/s41572-020-00240-3
Foerster F, Gairing SJ, Ilyas SI, Galle PR (2022) Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology. https://doi.org/10.1002/hep.32447
Gairing SJ, Thol F, Müller L, Hahn F, Thomaidis T, Czauderna C et al (2021) The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. JCM 10:2732. https://doi.org/10.3390/jcm10122732
Michel M, Hess C, Kaps L, Kremer WM, Hilscher M, Galle PR et al (2021) Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis. Sci Rep 11:20506. https://doi.org/10.1038/s41598-021-00119-7
Gairing SJ, Müller L, Kloeckner R, Galle PR, Labenz C (2022) Review article: post-TIPSS hepatic encephalopathy-current knowledge and future perspectives. Aliment Pharmacol Ther. https://doi.org/10.1111/apt.16825
Gairing SJ, Anders J, Kaps L, Nagel M, Michel M, Kremer WM et al (2022) Evaluation of IL-6 for Stepwise Diagnosis of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis. Hepatol Commun 6:1113–1122. https://doi.org/10.1002/hep4.1883
Michel M, Labenz C, Anders M, Wahl A, Girolstein L, Kaps L et al (2022) Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV. Hepatol Commun. https://doi.org/10.1002/hep4.1958
Michel M, Schattenberg JM (2020) Leberspezifische Diagnostik bei der nichtalkoholischen Fettlebererkrankung (NAFLD) – wann kann die Leberbiopsie ersetzt werden? Z Gastroenterol 58:1233–1240. https://doi.org/10.1055/a-1291-8483
Rights and permissions
About this article
Cite this article
Mitteilungen der GARPS. Gastroenterologie 17, 279–280 (2022). https://doi.org/10.1007/s11377-022-00632-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11377-022-00632-9